Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes

Documenti analoghi

• Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial
  di: Yoko Takatsuna, et al.
  Pubblicazione: (2026)
• Effect of sodium–glucose cotransporter 2 inhibitors on serum low‐density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus
  di: Tasuku Imada, et al.
  Pubblicazione: (2024)
• The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression
  di: Yen‐Chen Chiu, et al.
  Pubblicazione: (2025)
• Clinical use and monitoring of adverse effects of sodium‐glucose cotransporter‐2 inhibitors in persons with type 1 diabetes mellitus
  di: Chinatsu Sakai, et al.
  Pubblicazione: (2025)
• Comment on “The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression”
  di: Shyam Sundar Sah, et al.
  Pubblicazione: (2025)